Biguanide / AMPK activator

Plain-language summaryIntrigue 85 / 100

Metformin, sold as Glucophage, is the most prescribed diabetes drug in the world. Beyond glucose control, it has emerging interest in longevity; the TAME trial is investigating whether metformin slows aging in humans. The mechanism involves AMPK activation and mTOR inhibition. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished, active research

49/100

Deeply mature diabetes workhorse with a genuinely interesting longevity research program that cant fully rescue the novelty deficit

Look, metformin is one of those compounds where the interesting question isnt whether it works for its approved indication. It obviously does. Over 150 million people take it daily, the UKPDS gave us two decades of outcome data, and hepatic gluconeogenesis suppression via AMPK has been replicated by basically every lab that looked at it. The diabetes case is closed. So why are we in a research library talking about it?

The honest answer is the TAME trial. Targeting Aging with Metformin, led by Nir Barzilai at Einstein, is the first FDA-sanctioned trial explicitly designed to test a drug against biological aging endpoints in non-diabetic adults. Thats a genuinely novel use case for a 70-year-old molecule, and it drags metformin back into serious investigator conversations even if the compound itself isnt new. The trial is also methodologically important: it will establish a framework for what aging trial endpoints look like, independent of whether metformin succeeds or fails. That has bench value beyond the compound.

The cancer-prevention signal is real but messy. Observational data from diabetic cohorts shows reduced incidence across several cancer types, and multiple groups have proposed mechanisms linking AMPK activation to mTORC1 suppression and downstream effects on tumor metabolism. But those are diabetic populations on therapeutic doses, and the confounding is significant. We dont think the cancer signal is strong enough to be a primary research driver in isolation. It’s corroborating, not conclusive.

What we dont love: the mechanism isnt elegant. Complex I inhibition producing AMPK activation is blunt-instrument pharmacology. The compound hits a lot of things, the dose-response is shallow, and oral bioavailability is only 50 to 60 percent. Newer AMPK activators like AICAR and indirect effectors via AMPK-kinase biology are more useful as probes if you actually want to interrogate the pathway. Metformin is what you use when you want the whole messy biological gestalt, not when you want mechanistic precision.

The differentiation picture is also complicated. For metabolic research, semaglutide and tirzepatide have eclipsed metformin as the interesting objects. For longevity research, rapamycin via mTOR has a more defined mechanistic story and a more established preclinical track record. Metformin sits in an awkward middle space: too well-understood to be exciting, but active enough in ongoing clinical science to stay relevant. We think its worth having in the library primarily because of TAME and the longevity framing, not because of what it does at the bench.

Novelty: 22
Mechanism promise: 40
In-category differentiation: 45
Evidence quality: 72
Translational signal: 70
Research bench value: 62

Rationale Metformin scores well on evidence and translational signal for its primary indication but suffers badly on novelty and differentiation given its age and ubiquity; the TAME trial and cancer-prevention literature give it ongoing research relevance, but the compound is a known-quantity AMPK activator in a field now dominated by more elegant mechanistic actors.

Biguanide / AMPK activator

A first-line type 2 diabetes biguanide derived from French lilac (Galega officinalis), increasingly investigated for longevity and cancer prevention applications.

Abstract

Metformin (Glucophage; 1,1-dimethylbiguanide; CAS 657-24-9; molecular formula C4H11N5; molecular weight 129.16) is a biguanide derived from guanidine, originally identified in the 1920s from the French lilac (Galega officinalis) and approved in Europe in 1957 and the United States in 1995 for type 2 diabetes. The compound is the most prescribed oral antihyperglycemic globally. Primary mechanism is mild inhibition of mitochondrial complex I producing AMPK activation, with downstream reduction in hepatic gluconeogenesis, improved insulin sensitivity in skeletal muscle, and reduced gut glucose absorption. Beyond diabetes management, metformin has accumulated evidence in cancer prevention (reduced incidence in diabetics), cardiovascular outcomes (UKPDS, in obese diabetics), and possible longevity effects. The TAME trial (Targeting Aging with Metformin) is investigating longevity endpoints in non-diabetic populations. Pharmacokinetics: plasma half-life 4 to 9 hours; oral bioavailability 50 to 60 percent; renally excreted unchanged. Approved doses are 500 to 2550 mg per day in divided administrations. Lactic acidosis is the principal serious adverse event but is rare with appropriate renal function monitoring.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-096Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

Tag: Biguanide / AMPK activator

Metformin

Abstract

Read the full monograph